Prosthetic valve dysfunction post-bevacizumab: a transcatheter aortic valve replacement thrombosis case report.

ABSTRACT:

Background

Transcatheter aortic valve replacement (TAVR) thrombosis is a known complication, but its association with vascular endothelial growth factor (VEGF) inhibitors has not been previously reported.

Case summary

A 69-year-old male with previous TAVR developed new-onset prosthetic valve dysfunction after receiving bevacizumab for age-related macular degeneration. Echocardiography revealed moderate aortic stenosis with significantly elevated gradients compared to baseline. Following discontinuation of bevacizumab and initiation of systemic anticoagulation, valve function normalized at three-month follow-up.

Discussion

This first reported case of TAVR thrombosis potentially linked to bevacizumab therapy demonstrates a temporal relationship between drug administrati

SUBMITTER: Mourad D 

PROVIDER: S-EPMC12352106 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature